Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 5/20 | 0.40 |
| ▸ | TACR2 | P21452 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 8/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6951612 | 0.91 | TACR3 (0.47) | TACR3TACR2OPRM1DHODHPDE10A | |
| SCHEMBL7159967 | 0.90 | DHODH (0.46) | TACR3TACR2OPRM1DHODHLMNA | |
| SCHEMBL7076610 | 0.90 | DHODH (0.48) | TACR3TACR2OPRM1DHODHPDE10A | |
| Hydrochloric Acid SCHEMBL7077944 | 0.90 | TACR3 (0.47) | TACR3TACR2OPRM1DHODHPDE10A | |
| SCHEMBL7165599 | 0.89 | TACR3 (0.43) | TACR3TACR2OPRM1DHODHKCNH2 | |
| SCHEMBL7076609 | 0.88 | DHODH (0.43) | TACR3TACR2OPRM1DHODHKCNH2 | |
| SCHEMBL6956361 | 0.87 | TACR3 (0.38) | TACR3TACR2OPRM1DHODHPDE10A | |
| SCHEMBL6582324 | 0.84 | DHODH (0.42) | TACR3TACR2OPRM1DHODHPDE10A | |
| SCHEMBL7166157 | 0.83 | DHODH (0.50) | TACR3TACR2OPRM1DHODH | |
| SCHEMBL6586109 | 0.82 | TRPV4 (0.43) | TACR3TACR2OPRM1DHODHPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070574-A1 | Novel compounds | GLAXOSMITHKLINE SPA AND LABORATOIRE | 2005-03-31 | — | — | US | disclosed |
| EP-1339691-A1 | NOVEL COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002044154-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070574-A1 | Novel compounds | NR1H3, NR1H2, CNR1 | TACR3 301/4885TACR2 52/4885OPRM1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.